Health Industry

Latest KFF Health News Stories

Investors’ Deep-Pocket Push To Defend Surprise Medical Bills

KFF Health News Original

As lobbyists purporting to represent doctors and hospitals fight attempts to control surprise medical bills, it has become increasingly clear that the force behind the effort is not just medical professionals, but also investors from private equity firms.

Hospital Giant Sutter Health Faces Legal Reckoning Over Medical Pricing

KFF Health News Original

A long-awaited class-action lawsuit against Sutter is set to open this month in San Francisco Superior Court. The hospital giant stands accused of violating California’s antitrust laws by leveraging its market power to drive out competition and overcharge patients.

California Tries Again To Make Medication Abortions Available At Its Colleges

KFF Health News Original

A proposed state law would require on-campus health centers to provide students with the medicines that allow them to end an unwanted pregnancy. Former Gov. Jerry Brown vetoed a similar bill last year, but Gov. Gavin Newsom has said he would sign it.

Firing Doctor, Christian Hospital Sets Off National Challenge To Aid-In-Dying Laws

KFF Health News Original

In Colorado case, the right to aid a cancer patient’s death runs up against faith-based hospital policies. As more states have passed laws, about 1 in 6 acute care beds nationally is in a hospital that is Catholic-owned or -affiliated.

In India’s Slums, ‘Painkillers Are Part Of The Daily Routine’

KFF Health News Original

As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients’ pain, the nation’s sprawling, cash-fed health care system is ripe for misuse.

Beset By Lawsuits And Criticism In U.S., Opioid Makers Eye New Market In India

KFF Health News Original

What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.